Frazier Healthcare Partners

General Partner on the Growth Buyout team who joined in 2019, representing Frazier on boards including United Derm Partners and RevSpring. Previously a Principal at Norwest Equity Partners. Holds an MBA from Harvard Business School.

Joined Frazier in 2024 as a General Partner on the Structured Solutions team. Previously spent over five years at SVB Capital / WestRiver Group and held roles at Comerica Bank. Holds a BA in Accounting from the University of Puget Sound.

General Partner on the Growth Buyout team who leads Frazier's New York office, joining in 2012. Serves on boards including AirLife and CSafe. Previously an Analyst at RBC Capital Markets. Holds a BS in Economics from Wharton.

General Partner on the Growth Buyout team who joined in 2016, serving on boards including CareTria and Vatica Health. Previously spent five years at Kohlberg & Company and worked at JPMorgan. Holds a BS from Brigham Young University.

Joined Frazier in 1991 and has served on the firm's Management and Investment Committees, leading the Buyout team since 1995. He has served on boards of numerous portfolio companies including CHG Healthcare and Solis Mammography. Holds an MBA from NYU Stern and a BA from the University of Pennsylvania.

Joined Frazier in April 2023 as a talent leader with a track record of scaling organizations. Previously on the management team at Bridgewater Associates for nearly two decades as it grew to 1500 people and $150 billion AUM.

Joined Frazier in February 2024 as a Partner on the Structured Solutions team. Previously spent five years at SVB Capital / WestRiver Group and eight years at Comerica Bank. Holds a BA and MBA from Washington State University.

Partner on the Growth Buyout team who joined in 2016 and serves on boards including Tri-Imaging Solutions. Previously worked at The Edgewater Funds and CIVC Partners. Holds a BS in Biomedical Engineering and an MBA from Northwestern.

Joined Frazier in 2016, serving on boards including Altruix and Vatica Health. Previously an Analyst at Harris Williams & Co. Holds a BS in Business Administration from UNC Chapel Hill.

Brent Fierro is a growth equity investor at FTV Capital focused on financial technology and services, where he has worked for over 12 years since joining in 2013. He previously was an investment banking analyst in the financial institutions group at Houlihan Lokey and began his career at the New York Stock Exchange in strategy and data analytics.

Shalom Nahum joined Gemini in 2007 as Senior Controller and became CFO in 2014, focusing on fund management, valuation, and performance analysis. He previously worked as Controller at IBC and Senior Accountant at KPMG, and holds a BA in Business Administration and an MBA in Finance.

Dan Estes is a General Partner at Frazier Life Sciences, which he joined in 2011, where he invests in development-stage and commercial-stage pharmaceutical companies. He has co-founded and helped launch several portfolio companies and previously worked as a management consultant in McKinsey & Company's healthcare practice, advising pharmaceutical and biotech firms on R&D and business development strategy. He holds a Ph.D. in Biomedical Engineering from the University of Michigan and a B.S. in Electrical Engineering from Stanford University.

Gordon Empey is Chief Operating Officer, General Counsel, and a Partner at Frazier Life Sciences, which he joined in 2017, overseeing the firm's legal, operations, investor relations, compliance, HR, IT, and administrative functions. He has more than 25 years of experience advising venture capital investors and life sciences companies, previously serving as a partner at Cooley LLP and as EVP and General Counsel at Radiant Research, and earlier as General Counsel of the Frazier-sponsored SPAC that merged to form NewAmsterdam Pharma. He holds a J.D. from UC Berkeley (Boalt Hall) and a B.A. in History from Colgate University, and earlier served as an officer in the U.S. Navy Judge Advocate General Corps.

Jamie is a General Partner and Portfolio Manager at Frazier Life Sciences, which he joined in 2016, investing in private and public biotechnology companies. He co-leads Frazier's public equity investment strategy and serves as co-Portfolio Manager of the Frazier Life Sciences Public Fund alongside Albert Cha. Before Frazier, he was a management consultant at the Boston Consulting Group within its Healthcare Practice, and he holds an M.D. from the University of Southern California and a B.A. from Middlebury College.

Patrick Heron co-leads Frazier's Life Sciences team and is a Managing Partner and co-founder of that team, having joined the firm in 1999 and opened its Palo Alto office in 2003. He invests across therapeutics, from early-stage drug development to commercial-stage pharmaceutical companies. Before Frazier, he helped build McKinsey & Company's West Coast biotechnology consulting practice, and he holds an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina at Chapel Hill.

Joined Frazier in July 2023 as a Senior Associate and was promoted to Vice President in August 2025. Involved with portfolio companies including CareTria and RevSpring. Previously a Senior Manager at Zymergen and Associate Director at UBS. Holds an MBA from Wharton.

Joined Frazier in 2019 and serves on the board of RevSpring. Previously worked at McKinsey, co-founded a startup, and held roles at Credit Suisse and Morgan Stanley. Holds an MBA and MPH from UC Berkeley.

Joined Frazier in February 2024 as a Vice President on the Structured Solutions team. Previously a Vice President at SVB Capital and Associate at Silicon Valley Bank focusing on venture debt. Holds a BA from Brandeis University.

Joined Frazier in July 2022 as a Senior Associate and was promoted to Vice President in 2024. Involved with portfolio companies including Adare Pharma Solutions. Previously a Senior Associate at the Abu Dhabi Investment Authority. Holds an MBA from Wharton.

Joined Frazier in October 2022 as an Associate, rising to Vice President. Involved with portfolio companies including AirLife and EPTAM Precision. Previously an Associate at Carlyle and Analyst at J.P. Morgan. Holds a BS in Business from NYU.

Joined Frazier in 2016 as an Associate, later spending time at portfolio company Leiters before rejoining the investment team in 2019. Sits on boards including CareTria and LUX Infusion. Holds a BA in Economics from Middlebury College.

Joined Frazier in August 2022 with over 20 years of M&A and management consulting experience, leading integration and value maximization efforts across the portfolio. Previously a Senior Director at A&M's PE practice, at EY-Parthenon, and six years at McKinsey.

Joined Frazier in July 2025 as a Vice President on the Growth Buyout team. Previously spent four years at New Mountain Capital and worked at WindRose Health Investors and Jefferies. Holds an MBA from Wharton.

Laura Gleason Moore is Director of Operations at Berggruen Holdings, where she oversees operational strategy, processes, and performance across multiple sectors and regions in coordination with the CFO and other senior leaders. She joined the company more than seven years ago as Administrative Director before advancing to her current role, working on structuring, financing, compliance, investment projects, business development, and communications. Her earlier career included real estate positions at Colony Capital, GPI Companies, and Joseph Cohen Real Estate, and she studied English and Business at USC.

Maria Fardis joined Frazier Life Sciences as a Venture Partner in 2021 and has more than 20 years of scientific and management experience across public and private companies. She currently serves as CEO of Lassen Therapeutics and previously held leadership roles including President and CEO of Iovance Biotherapeutics, COO of Acerta Pharma, and senior positions at Pharmacyclics and Gilead Sciences. She holds a Ph.D. in Organic Chemistry from UC Berkeley, a B.S. in chemistry from the University of Illinois, Urbana-Champaign, and an M.B.A. from Golden Gate University.

Joined Frazier in April 2023 with over 20 years of IT experience in architecture, delivery, and cost optimization. Previously Senior Director of Data Engineering at Mercury Healthcare/WebMD and Director at Optum. Holds a BS and BBA from Minnesota Duluth and MBA from Carlson.

Joined Frazier in August 2024 as an Associate on the Growth Buyout team. Previously an Analyst at TD in Vancouver. Holds a Bachelor of Commerce from the University of British Columbia.

Joined Frazier in 2016 and became a Center of Excellence Partner, later serving as COO of the Center of Excellence team focused on human capital and ESG. Previously a Partner at Green Peak and expert at McKinsey. A former U.S. Army Aviation Officer. Holds a Masters from Columbia and BS from West Point.

Center of Excellence Partner for technology and innovation since 2015, with extensive experience in IT applications and infrastructure. Previously Director of Applications for TridentUSA. Holds a BA from the University of Washington.

Joined Frazier in April 2025 as a Center of Excellence Partner for finance and operations, bringing over two decades of experience. Serves on the board of Knipper Health. Previously CFO at IMG Academy and CPS. Holds a BBA from Franklin University and MBA from Vanderbilt.

Joined Frazier in January 2023, rising to Partner by 2026, supporting portfolio companies in finance, supply chain, and analytics. Previously spent nearly 10 years at Providence health system. Holds a BA from Middlebury and MBA from University of Michigan Ross.

Joined Frazier in April 2026 as a Center of Excellence Principal for Data & AI on the Growth Buyout team. Previously SVP and CIO at MultiCare Health System. Holds an MS from Brown and an MBA from Pacific Lutheran University.

Joined Frazier in July 2024 as an Associate on the Growth Buyout team. Previously an investment banking analyst at Deloitte Corporate Finance. Holds a BS and BA from UNC Chapel Hill.

Joined Frazier in August 2023 as an Associate and was promoted to Senior Associate in 2025. Previously an Investment Banking Analyst at Deutsche Bank. Holds a BA in Economics from Northwestern.

Re-joined Frazier as an Executive in Residence focused on home health, hospice and related areas. Previously co-founder and CFO of Abode Healthcare, a Frazier portfolio company acquired by BrightSpring Healthcare, and earlier worked at Trident Capital, Spectrum Equity Investors, and Alex. Brown.

Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an investment banker at TD Cowen. Holds a BS in Biological Sciences from Cornell.

Joined Frazier in 2021 with over 20 years of experience in enterprise risk management, regulatory compliance, and information security. Previously CISO of a public multinational company and led IT compliance at a home-healthcare firm. Prior roles at KPMG and Protiviti.

Joined Frazier in October 2024 as a Senior Associate on the Growth Buyout team. Previously a Senior Associate at Grant Avenue Capital and Associate at Piper Sandler. Holds a BBA from the University of Michigan.

Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an Investment Banking Associate at Deutsche Bank. Holds a BA in Mathematics and Economics from Hamilton College.

Joined Frazier in July 2024 as an Associate on the Growth Buyout team. Previously an investment banker at Solomon Partners and Fenchurch Advisory Partners. Holds a BA in Classics from the University of Bristol.

Joined Frazier in February 2022 with over 20 years of experience in corporate FP&A and data analytics. Previously Director of Finance at Fiserv and Director of FP&A at Healthcare Solutions. Holds a BBA in Accounting from Georgia State University.

Joined Frazier in January 2023 as a Center of Excellence Vice President for legal, with over 10 years of legal experience. Previously VP, Senior Corporate Counsel at AmTrust and an Associate at Goodwin Procter. Holds a BA from Cornell and JD from Fordham.

Joined Frazier in November 2021 with over 10 years of experience in data science and analytics focused on healthcare. Previously Director of Data Science at Healthgrades and roles at Verizon and Capital BlueCross. Holds a BS from Bucknell and MS from Northwestern.

Joined Frazier's Growth Buyout team in 2005 as a Center of Excellence Partner for finance and operations. Serves on the board of AirLife and various public boards. Previously CFO of First Health. A CPA who began at Peat Marwick. Holds a BA from Luther College.

Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an Investment Banking Analyst at Bank of America. Holds a BBA in Finance from Notre Dame.

Joined Frazier in August 2021 as a Center of Excellence Partner for Data & AI on the Growth Buyout team. Previously SVP and GM of Data, Analytics, and Insights at Clarivate and 18 years at Decision Resources Group. Holds a BASc from the University of Toronto.

Joined Frazier in January 2026 as a Center of Excellence Principal for sales excellence with over 20 years in healthcare and life sciences. Previously VP and Head of the Cell & Gene Service Line at Cencora and senior roles at CVS Health. Holds a BS from the University of Arizona.

Joined Frazier in September 2025 as a Senior Associate on the Growth Buyout team. Previously a Senior Associate at The Vistria Group and Analyst at William Blair. Holds a BA in Economics from the University of Chicago.

Joined Frazier in July 2026 as Director of Deal Origination on the Center of Excellence team. Previously a business development professional at Lincoln International and at PitchBook Data. Holds a BA in Communication from North Carolina State University.

Joined Frazier in July 2023 as an Associate and was promoted to Senior Associate in 2025. Previously an Investment Banking Analyst at TD Cowen. Holds a BA in Economics from Claremont McKenna College.

Joined Frazier in May 2024 focused on women's health and wellness. Former CEO of Thinx, which she scaled to a $130M+ brand and sold to Kimberly Clark, with prior executive roles at eBay, Fab.com, Thomson Reuters, Dow Jones, Yahoo, and Disney.

Joined Frazier in August 2021, involved with portfolio companies including Konovo and Altruix. Previously an Associate at Sheridan Capital Partners and Analyst at William Blair. Holds a BA in Economics from Indiana University.

Joined Frazier in August 2022 as a Center of Excellence Partner for M&A with over 20 years of consulting and transaction experience. Previously a Senior Director at A&M and roles at EY-Parthenon and McKinsey. Holds an MBA from Cornell.

Joined Frazier in June 2026 focused on clinical services investments. Former CEO of Kindeva Drug Delivery and SCA Pharmaceuticals, with a career spanning pharmaceutical contract development and manufacturing (CDMOs).

Joined Frazier in July 2025 as an Associate on the Growth Buyout team. Previously an Investment Banking Analyst at Piper Sandler. Holds a BA in Economics from UC San Diego.

Joined Frazier in April 2023, promoted to Center of Excellence Principal for commercial strategy and marketing in 2025. Previously VP of Commercial Strategy at Cerberus and Director of Strategy at Publicis Groupe. Holds a BA from UPenn and MBA from NYU Stern.

Joined Frazier in February 2025 as Director of Data & AI with over 15 years in data science and healthcare analytics. Previously Senior Director of Data Science at Eversana. Holds an MS from McMaster University and a BS from the University of Khartoum.

Joined Frazier in May 2021 as a member of the Center of Excellence Technology and Innovation team with over 16 years in healthcare. Previously Director of IT Operations at SOCTelemed. Holds a BS from George Mason University and PMP certification.

Joined Frazier in 2014 as General Counsel and Center of Excellence Partner for legal and operations. Previously General Counsel of Aptalis Pharmaceuticals and senior executive at APP Pharmaceuticals. Holds a JD from Santa Clara and an LLM from Boston University.

Joined Frazier in May 2024 as a Center of Excellence Partner for Data & AI on the Growth Buyout team. Previously SVP of AI Products and Platforms at Optum and founder of OptumLabs' Center for Applied Data Science. Holds a BS in Computer Science from Trinity College.

Joined Frazier in January 2025 as a Center of Excellence Principal for technology and innovation with over 20 years in tech. Previously VP in portfolio operations at Brookfield Asset Management and Cerberus. Holds a BS from Amravati University and MBA from IIM Lucknow.

Joined Frazier in July 2024 as a Center of Excellence VP of Corporate Development, promoted to Principal in 2026. Founded M&A advisory firm Black Eagle Advisors and previously led corporate development at MiX Telematics. Holds a BS from USC and MBA from Harvard.

Joined Frazier in June 2026 focused on healthcare information technology. Former CEO of HealthEdge, which he grew to $400M+ revenue through two exits, and previously a healthcare venture capital partner at the Psilos Group.

Clarissa Berman is a Principal at Frazier Healthcare Partners. Her experience spans private and public equities, business and corporate strategy, and start-ups.

Investment consultant supporting investment banks and management firms across traditional and alternative investments including hedge funds, fund of funds, private equity, VC, and wealth management.

Chris Peetz is Chief Executive Officer and co-founder of Mirum Pharmaceuticals. He brings experience in finance, corporate development, marketing, and executive leadership within the biopharmaceutical industry.

Gordon McMurray joined Frazier Life Sciences as an Entrepreneur-in-Residence in March 2020 and has over 18 years of experience in drug discovery and development. He previously co-founded and served as Chief Scientific Officer at Outpost Medicine, and earlier held senior R&D roles at Pfizer across neuroscience, pain, sensory disorders, and urology, as well as a lectureship and lab head position in pharmacology at Oxford University. He earned a B.Sc. and Ph.D. from Queen's University Belfast.

Ian W. Mills is an Entrepreneur-in-Residence at Frazier Life Sciences, having joined in March 2020, with a background as a pharmaceutical development executive. He previously served as Chief Medical Officer at Outpost Medicine and Head of Clinical Development at Mitsubishi Tanabe Pharma Europe, and spent over 15 years at Pfizer in clinical and development leadership roles. He holds an MA in Natural Sciences from Cambridge University and a medical degree and medical doctorate from Oxford University.

Investor, operator, and board director with 25+ years scaling consumer and healthcare businesses; former CEO and board member of Thinx, with prior leadership roles at eBay, Yahoo, Thomson Reuters, Dow Jones, Fab.com, and Disney.

Angel Martin is a Vice President at Frazier Life Sciences, which she joined in 2021 to evaluate investment opportunities in the life sciences sector. She previously worked as an Investment Fellow with Vertex Ventures Healthcare and held roles as Director of Research and Venture Grants at Emerson Collective, Health and Research Director of the Friedreich Ataxia Research Alliance. She holds a Ph.D. in Pharmacology and Cancer Biology from Duke University and a B.A. from the University of Michigan, Ann Arbor.

Joe Cabral is a Partner at Frazier Life Sciences, which he joined in 2021, working on the firm's private investment and company creation strategies. Before that, he worked in venture creation at Flagship Pioneering and was a founding team member at Generate:Biomedicines in protein engineering and strategy roles, and earlier was an early employee at Moderna focused on molecular biology and informatics. He holds an MBA from the University of Michigan's Ross School of Business, and an M.S. in Genomics and a B.S. in Biology from the University of Connecticut.